Welcome
Welcome to the Wagner lab!
The group is dedicated to the development, and preclinical as well as clinical testing, of HIV candidate vaccines. According to the necessity of rational vaccine design the group is focussing on various aspects of epidemiology, viral pathogenesis and morphogenesis, HIV replication, and vaccine manufacturing, including preclinical and clinical monitoring of antigen-specific B- and T-cell responses. The group is fully financed by national and international grants such as the Bavarian Research Foundation (Bayerische Forschungsstiftung), the German Ministry of Education and Research (BMBF), the European Union and the Bill & Melinda Gates Foundation.
- startbild
News
Start der Antikörperstudie zu bislang unerkannten COVID19-Infektionen im Landkreis Tirschenreuth
Regensburg, 2020-05-08: Bayern startet eine neue Studie zu COVID19-Infektionen: Mit Hilfe einer zufälligen Stichprobenanalyse im Landkreis Tirschenreuth wollen Wissenschaftler der Universität Regensburg sowie der... > more
New project granted
Regensburg, 2018-08-14: New project granted: The Wagner lab will be partner in the project "Clinical trial of a DIOS Trivalent Haemorrhagic Fever Vaccine" (HFVac3). Based on the excellent outcomes of the two predecessor... > more
New project granted
Regensburg, 2018-05-18: New project granted: The Wagner lab will be partner in the project "A therapeutic vaccine to eradicate pre-malignant HPV16 and HPV18 infection and prevent cancer" (THERIN). In cooperation with... > more
New project granted
Regensburg, 2017-03-17: The Wagner lab will participate in the "Trivalent Lassa, Ebola and Marburg viral vaccine" (Tri-LEMvac) consortium, funded by innovate UK and coordinated by Prof. Jonathan Heeney from Darwin... > more
Excellent project completion
Regensburg, 2017-02-10: The triennial project term of the research consortium "ForBIMed - Biomarkers in Infection Medicine", generously funded by the Bavarian Research Foundation, ended this January. In the context of... > more